Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Strongbridge Bio Ord (SBBP)

Strongbridge Bio Ord (SBBP)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
2.00 +0.03 (+1.52%) 10/05/21 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.00 unch (unch) -
Quote Overview for Tue, Oct 5th, 2021
Day Low
1.95
Day High
2.06
Open 1.96
Previous Close 1.97 1.97
Volume 684,600 684,600
Avg Vol 234,660 234,660
Stochastic %K 19.38% 19.38%
Weighted Alpha -28.48 -28.48
5-Day Change -0.06 (-2.91%) -0.06 (-2.91%)
52-Week Range 1.85 - 4.26 1.85 - 4.26
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,658
  • Shares Outstanding, K 67,829
  • Annual Sales, $ 30,730 K
  • Annual Income, $ -45,080 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.59
  • Price/Sales 4.35
  • Price/Cash Flow N/A
  • Price/Book 3.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings N/A on 08/05/21
  • Next Earnings Date 11/04/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +2.56%
on 10/05/21
Period Open: 2.24
2.32 -13.79%
on 09/10/21
-0.24 (-10.71%)
since 09/03/21
3-Month
1.85 +8.11%
on 08/16/21
Period Open: 3.08
3.19 -37.30%
on 07/06/21
-1.08 (-35.06%)
since 07/02/21
52-Week
1.85 +8.11%
on 08/16/21
Period Open: 2.16
4.26 -53.05%
on 02/16/21
-0.16 (-7.41%)
since 10/05/20

Most Recent Stories

More News
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”)...

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland...

SBBP : 2.00 (+1.52%)
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ:...

SBBP : 2.00 (+1.52%)
XERS : 4.16 (+5.32%)
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have...

SBBP : 2.00 (+1.52%)
XERS : 4.16 (+5.32%)
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris

SBBP : 2.00 (+1.52%)
XERS : 4.16 (+5.32%)
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals

SBBP : 2.00 (+1.52%)
XERS : 4.16 (+5.32%)
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Xeris stockholders vote “FOR”...

SBBP : 2.00 (+1.52%)
XERS : 4.16 (+5.32%)
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update

~ Reports KEVEYIS ®  (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the...

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the...

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization...

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with the Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization...

SBBP : 2.00 (+1.52%)
Axogen, Inc. Appoints John H. Johnson to Board of Directors

Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

AXGN : 15.89 (+0.57%)
SBBP : 2.00 (+1.52%)
VSTM : 4.64 (+2.65%)
Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve

~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~

SBBP : 2.00 (+1.52%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates SBBP, RFL, CLDB, MPB; Shareholders are Encouraged to Contact the Firm

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

SBBP : 2.00 (+1.52%)
RFL : 1.7000 (+4.29%)
CLDB : 29.15 (+3.81%)
MPB : 24.25 (-0.41%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of CLDR, KSU, SBBP, and DISCA Mergers

WILMINGTON, Del., July 02, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

CLDR : 15.99 (+0.06%)
KSU : 293.59 (-1.69%)
SBBP : 2.00 (+1.52%)
DISCA : 24.43 (+5.90%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MMAC, XEC, SBBP, SLCT; Shareholders are Encouraged to Contact the Firm

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

MMAC : 27.77 (+0.04%)
XEC : 87.20 (-3.11%)
SBBP : 2.00 (+1.52%)
SLCT : 18.88 (-2.43%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds MMAC, SBBP, HRVSF, and XOG Shareholders About Its Ongoing Investigations

NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) --

MMAC : 27.77 (+0.04%)
SBBP : 2.00 (+1.52%)
HRVSF : 3.2200 (+0.94%)
XOG : 68.54 (+2.87%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds SNX, MMAC, SBBP, and HRVSF Shareholders About Its Ongoing Investigations

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) --

SNX : 101.96 (+0.11%)
MMAC : 27.77 (+0.04%)
SBBP : 2.00 (+1.52%)
HRVSF : 3.2200 (+0.94%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ARPO, ALTA, MMAC, SBBP; Shareholders are Encouraged to Contact the Firm

NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

ARPO : 2.20 (-0.90%)
ALTA : 44.16 (-1.25%)
MMAC : 27.77 (+0.04%)
SBBP : 2.00 (+1.52%)

Business Summary

Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly,...

See More

Key Turning Points

3rd Resistance Point 2.17
2nd Resistance Point 2.11
1st Resistance Point 2.06
Last Price 2.00
1st Support Level 1.95
2nd Support Level 1.89
3rd Support Level 1.84

See More

52-Week High 4.26
Fibonacci 61.8% 3.34
Fibonacci 50% 3.06
Fibonacci 38.2% 2.77
Last Price 2.00
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar